ObvioHealth and SPRIM PRO Launch Integrated Digital Patient Monitoring and Clinical Support Solution for High-Risk Therapies

New strategic offering combines digital health technology with clinical operations and patient support to help pharmaceutical companies modernize patient monitoring for REMS programs and other therapies requiring enhanced clinical oversight.

NEW YORK, Sept. 10, 2026 /PRNewswire/ -- The pharmaceutical industry is entering a new era of increasingly specialized therapies that require more intensive patient monitoring beyond the point of care. Specialty medicines have accounted for more than half of all novel FDA drug approvals since 2012, reflecting a fundamental shift toward increasingly complex treatments that require enhanced patient monitoring, including Risk Evaluation and Mitigation Strategy (REMS) programs and other therapies requiring structured clinical oversight. A 2026 peer-reviewed analysis of FDA approvals from 2000–2024 found that 57% of novel therapies approved during that period were specialty medicines.¹

As pharmaceutical pipelines continue to evolve toward specialty medicines, biologics, cell and gene therapies, and other high-risk treatments, sponsors are seeking new approaches to deliver the clinical oversight these therapies require while reducing burden on patients, healthcare providers, and care settings.

To help meet this growing need, ObvioHealth and SPRIM PRO today announced the launch of their Integrated Digital Patient Monitoring and Clinical Support Solution for High-Risk Therapies—a new strategic business offering that integrates digital health technology, clinical operations, and patient support services into a single solution.

Designed for pharmaceutical and biotechnology companies developing or commercializing therapies that require enhanced patient monitoring, the offering supports REMS programs, broader patient support initiatives, specialty therapeutics, infusion therapies, advanced biologics, cell and gene therapies, and other high-touch treatment pathways where ongoing clinical oversight is essential.

By combining ObvioHealth's ObvioGo® digital health platform with SPRIM PRO's more than 25 years of clinical research, patient support, and remote patient monitoring expertise, the organizations provide pharmaceutical sponsors with a unified approach to designing, implementing, and managing patient monitoring programs across the product lifecycle. Rather than coordinating multiple technology vendors and service providers, sponsors can work with a single partner to design, deploy, and manage patient monitoring programs from clinical development through commercialization.

The offering enables sponsors to extend clinical oversight beyond traditional care settings, when clinically appropriate, by integrating digital technology, clinical support services, and remote patient engagement into a seamless patient experience.

For therapies requiring extended post-administration observation, sponsors may, when clinically appropriate and aligned with the study protocol or product labeling, incorporate technology-enabled remote monitoring as part of a hybrid patient monitoring strategy. Digital symptom reporting, telehealth interactions, configurable escalation pathways, and real-time clinical oversight help maintain visibility into patient safety while providing greater flexibility for patients, healthcare providers, and care teams. SPRIM PRO procures, stores and ships direct to patients, enabling seamless and robust care at an affordable price.

"Technology alone doesn't transform patient monitoring—it must be paired with clinical expertise and thoughtful patient engagement," said Ivan Jarry, Chief Executive Officer of ObvioHealth. "By combining ObvioHealth's digital platform with SPRIM PRO's deep clinical experience, we're helping pharmaceutical companies build patient monitoring programs that are scalable, patient-centered, and designed to support the evolving needs of today's most advanced therapies."

"As therapeutic regimens become increasingly complex, sponsors need flexible monitoring solutions that extend beyond traditional models of care," said Dr. Susan Dallabrida, Chief Executive Officer of SPRIM PRO. "For more than 25 years, SPRIM PRO has partnered with global healthcare organizations to design and execute complex remote patient monitoring and patient support programs. We are very excited about our partnership with ObvioHealth because we are delivering an integrated solution that combines technology, clinical expertise, and decentralized operational excellence to help sponsors navigate the next generation of patient monitoring with certainty."

The Integrated Digital Patient Monitoring and Clinical Support Solution is designed to support organizations from late-stage clinical development through commercialization and post-market patient support. Whether supporting REMS programs, broader patient support initiatives, specialty pharmaceuticals, advanced therapeutics, or other high-touch treatment pathways, the offering provides the flexibility to tailor patient monitoring workflows to the unique requirements of each therapy.

As the healthcare landscape continues to evolve, ObvioHealth and SPRIM PRO share a common vision: enabling technology-supported, clinically guided patient monitoring that expands access, improves operational efficiency, and delivers a better experience for patients, providers, and sponsors alike.

About ObvioHealth

ObvioHealth is a digital health technology company advancing decentralized clinical research and remote patient monitoring through its configurable ObvioGo® platform. Purpose-built for clinical research and patient monitoring, ObvioGo enables organizations to deliver digital engagement, electronic clinical outcome assessments (eCOA), eConsent, telehealth, remote data collection, and configurable workflows that improve participant experiences, operational efficiency, and data quality across decentralized, hybrid, and site-based programs.

About SPRIM PRO

SPRIM PRO is a global CRO and patient healthcare organization with more than 25 years of experience supporting pharmaceutical, biotechnology, medical device, and consumer health organizations. The company provides clinical operations, remote clinical care, telehealth, logistics support, storage and shipping and digital training. Through its multidisciplinary expertise and global network, SPRIM PRO helps sponsors design and execute patient-centered programs that accelerate innovation while maintaining the highest standards of quality, compliance, and care.

Source

¹ Knox SE, Brennan CH, Enright DE, Neumann PJ, Chambers JD. FDA Approvals of Specialty Drugs, 2000–2024. Health Affairs Scholar. 2026;4(2):qxag035.

SOURCE ObvioHealth